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Abstract
Phylogenetic analyses have provided strong evidence that amino acid changes in spike (S) protein of animal and human
SARS coronaviruses (SARS-CoVs) during and between two zoonotic transfers (2002/03 and 2003/04) are the result of positive
selection. While several studies support that some amino acid changes between animal and human viruses are the result of
inter-species adaptation, the role of neutralizing antibodies (nAbs) in driving SARS-CoV evolution, particularly during intra-
species transmission, is unknown. A detailed examination of SARS-CoV infected animal and human convalescent sera could
provide evidence of nAb pressure which, if found, may lead to strategies to effectively block virus evolution pathways by
broadening the activity of nAbs. Here we show, by focusing on a dominant neutralization epitope, that contemporaneous-
and cross-strain nAb responses against SARS-CoV spike protein exist during natural infection. In vitro immune pressure on
this epitope using 2002/03 strain-specific nAb 80R recapitulated a dominant escape mutation that was present in all 2003/
04 animal and human viruses. Strategies to block this nAb escape/naturally occurring evolution pathway by generating
broad nAbs (BnAbs) with activity against 80R escape mutants and both 2002/03 and 2003/04 strains were explored.
Structure-based amino acid changes in an activation-induced cytidine deaminase (AID) ‘‘hot spot’’ in a light chain CDR
(complementarity determining region) alone, introduced through shuffling of naturally occurring non-immune human VL
chain repertoire or by targeted mutagenesis, were successful in generating these BnAbs. These results demonstrate that
nAb-mediated immune pressure is likely a driving force for positive selection during intra-species transmission of SARS-CoV.
Somatic hypermutation (SHM) of a single VL CDR can markedly broaden the activity of a strain-specific nAb. The strategies
investigated in this study, in particular the use of structural information in combination of chain-shuffling as well as hot-spot
CDR mutagenesis, can be exploited to broaden neutralization activity, to improve anti-viral nAb therapies, and directly
manipulate virus evolution.
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Introduction
A novel coronavirus (CoV), severe acute respiratory syndrome
coronavirus (SARS-CoV), caused a worldwide epidemic of SARS
with a fatality rate of 9.6% in 2002/03 and later reemerged and
resulted in infection of four individuals with full recovery in the
winter of 2003/04 [1–5]. SARS-CoV has been demonstrated to be
a zoonotic disease that evolved in palm civet and human hosts.
The global outbreak that occurred in 2002/03 and the cluster of
2003/04 SARS cases were the result of two independent zoonotic
transfers from palm civets to humans [6–9]. Although palm civets
were identified as the hosts involved in human transmission,
evidence suggested the existence of another precursor reservoir.
Indeed bats, predominantly horseshoe bats, were later found to be
a natural reservoir of SARS-like-CoVs, and harbor more diverse
viruses than any other hosts [10–14]. Variants of SARS-like-CoVs
circulating in bats may cross the species barrier again and this
threat is enhanced by the large numbers of bats that often
congregate, their broad geographic distribution and their ability to
travel long distances. Diversity of host range and variant immune
pressures within the natural reservoir or intermediate hosts are
likely to continue to drive SARS-CoV evolution.
Phylogenetic analyses have provided clear evidence that amino
acid changes in spike (S) protein of animal and human viruses
obtained during and between the two zoonotic transfers were the
result of positive selection. These studies suggested that the S gene
underwent strong positive selection for the adaptation to human
hosts during the interspecies transmission; a positive selection
pressure during transmission within same species was also clearly
demonstrated [6–8]. The role that nAb-mediated immune
PLoS Pathogens | www.plospathogens.org 1 November 2008 | Volume 4 | Issue 11 | e1000197pressure played in driving the positive selection, particularly
during intra-species transmission, is still unknown.
Over the last several years, neutralizing human monoclonal
antibodies (mAbs) have been developed as potential therapeutics
for the prophylaxis and treatment of SARS [15–20]. NAbs-
mediated protection can also prevent the escape of mutant viruses
from cytotoxic T-lymphocytes that are commonly associated with
rapid disease progression and severity [21,22]. Although there has
not been a recent SARS-CoV outbreak, it is desirable to develop
effective Ab-based passive immunotherapy for this zoonotic
respiratory pathogen that might continue to evolve under immune
pressure within the animal kingdom and has the potential to
rapidly adapt in humans.
We previously developed a potent human nAb 80R against S
protein of both civet and human 2002/03 viral strains that
demonstrated profound protection against viral infection in a
SARS-CoV mouse model. Our studies revealed that 80R
recognizes a conformationally sensitive epitope located within
the receptor binding domain (RBD) [23]. A comprehensive
neutralization sensitivity/resistance profile for 80R was also
established based on the detailed epitope mapping and a co-
crystallographic structural study [23,24]. In this paper, we used
this nAb and detailed knowledge of its epitope to examine nAb
responses in convalescent serum samples from chronically exposed
civet farmers, 2002/03 and 2003/04 SARS outbreak patients, and
2004 civet cats. Our studies provide the first evidence that
contemporaneous strain-specific and cross-strain nAb responses
against S protein are present in natural civet cat and human
infection. In vitro neutralization escape studies with 80R recapit-
ulated a highly conserved escape mutation that also occurred
naturally from 2002/03 to 2003/04 viruses regardless of host
species. The structural features of human nAbs that were required
to broaden their activity to include binding to escape mutants was
also investigated. Indeed, among several different approaches
examined, amino acid changes in a single activation-induced
cytidine deaminase (AID) ‘‘hot spot’’ of a light chain CDR alone,
introduced through shuffling of naturally occurring non-immune
human variable light chains (VLs) or by targeted CDR
mutagenesis were sufficient to generate broad nAbs (BnAbs)
against a range of viral strains including neutralization escape
variants. These results have important implications for the
management of new emerging viral pathogens and provide a
strategy to directly manipulate virus evolution through Ab
blockade of escape pathways.
Results
Serologic analysis
Eleven randomly selected serum samples from patients who
developed SARS during the 2002/03 outbreak were analyzed for
their neutralizing activities against S protein pseudotyped viruses.
The S protein from Tor2 and GD03 viral strains that were used
are representative of the late phase of the 2002/03 outbreak and
2003/04 human cases, respectively. Phylogenetic analysis of
different viral isolates from human patients and civets of the two
epidemics demonstrated a close relationship of Tor2 and SZ3
(2003 Civets); while GD03 is closer to PC04 (2004 Civets) [8].
Though all 11 serum samples from 2002/03 outbreak were able to
neutralize Tor2 and GD03 pseudotyped viruses, the potency was
quite different (Fig. 1A). The 2002/03 patient serum samples are
statistically significantly more potent in neutralizing Tor2 than
GD03. In contrast, statistical analysis of 2004 civet cat sera showed
higher neutralizing activity against GD03 compared to Tor2
(Fig 1B). In addition, neutralization activity was found in three of
the four 2003/04 outbreak patient sera to be slightly higher
against GD03 strain compared to Tor2 (Fig. 1C). Interestingly,
surveillance sera samples collected from civet cat farmers in June
2003, a period between the 2002/03 and 2003/04 outbreaks,
showed the same neutralizing titers to Tor2 and GD03, likely
owing to their chronic exposure to the SARS-like-CoVs (Fig. 1D).
The Tor2-RBD binding activity of these serum samples was also
tested. Unexpectedly, there was higher binding activity of Tor2-
RBD with 2003 civet cat farmers’ serum than was seen with 2002/
03 patient sera (Fig. 1E). A further comparison of the ability of
different serum samples to compete for 80R binding to Tor2-RBD
showed that the 2002/03 patient sera competed for 80R’s binding
significantly stronger than did each of the 2003/04 serum samples
(Fig. 1F). Taken together, these two latter observations suggest that
a larger percentage of Tor2-RBD directed Abs in 2002/03 serum
samples are ‘‘80R-like’’ nAbs than in 2003/04 serum samples.
These results also demonstrate that contemporaneous-strain and
cross-strain nAb are produced in both humans and animals
following natural SARS-CoV/SARS-like-CoV infection.
Neutralization escape from 80R
Molecular evolution studies on SARS-CoVs during the 2002/
03 outbreak and between the two zoonotic transfers have provided
evidence of positive selection pressure in the S gene [8,9]. In vitro
neutralization escape studies using the 2002/03 strain specific nAb
80R were performed to simulate humoral immune pressure in vivo.
After incubation of plaque purified SARS-CoV (Urbani used here,
same as Tor2) with 80R, a total of 4 isolated plaques were picked,
viable viruses were obtained from all of these four plaques after
three passages in cell culture. All viruses were confirmed to be
80R-resistant at a concentration 100-fold greater than that needed
for neutralizing 90% of wild-type viruses. Sequencing of the
complete S gene of these four 80R-escape variants revealed one
common mutation at amino acid position 480. Three of the S
variants carried a mutation of lysine to alanine (D480A), and the
other one had a mutation of lysine to glycine (D480G). Although
four other mutations were also shown in the S protein, none of
them appeared more than once in the four escape variants and 3
of them were located outside the RBD (Table 1). We have
Author Summary
The SARS-CoV caused a worldwide epidemic of SARS in
2002/03 and was responsible for this zoonotic infectious
disease. The role of neutralizing antibody (nAb) mediated
immune pressure in the evolution of SARS-CoV during the
2002/03 outbreak and a second 2003/04 zoonotic trans-
mission is unknown. Here we demonstrate nAb responses
elicited during natural infection clearly have strain-specific
components which could have been the driving force for
virus evolution in spike protein during intra-species
transmission. In vitro immune pressure using 2002/03
strain-specific nAb 80R recapitulate a dominant escape
mutation that was present in all 2003/04 animal and
human viruses. We investigated how to generate a single
broad nAb (BnAb) with activity against various natural viral
variants of the 2002/03 and 2003/04 outbreaks as well as
nAb escape mutants. Remarkably, amino acid changes in
an activation-induced cytidine deaminase (AID) ‘‘hot spot’’
of somatic hypermutation and localized to a single VL CDR
were successful in generating BnAbs. These results provide
an effective strategy for generating BnAbs that should be
generally useful for improving immune based anti-viral
therapies as well as providing a foundation to directly
manipulate virus evolution by blocking escape pathways.
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PLoS Pathogens | www.plospathogens.org 2 November 2008 | Volume 4 | Issue 11 | e1000197Figure 1. Serologic analysis. A, 11 of convalescent serum samples were obtained from SARS patients of the 2002/03 outbreak in China.
Neutralizing activities of these serum samples were analyzed against pseudotyped viruses bearing the S protein of Tor2 or GD03 at indicated
dilutions. Data were shown in a box and whiskers graph. The box extends from 25th percentile to the 75th percentile, with a line at the median. The
whiskers above and below the box indicate the 95th and 5th percentiles. The dots above and below the box showed highest and lowest data points.
A symbol of ‘‘*’’ indicates the data points of a SARS-CoV negative healthy human serum sample. IC90 for each patient serum was calculated and the
statistic analysis was done with IC90 value using one way ANOVA for correlated samples. The same data presentation and the statistic analysis
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binding of 80R to S protein or RBD fragment (S318-510) [23] and
D480 is the key residue which forms a negative charged binding
interface patch with 80R [24]; mutation of 480 did not affect
binding of RBD of S protein to human ACE2 receptor [25] or
viral replication in Vero cells (data not shown). Therefore it is clear
that the D480A/G mutation sufficiently confers 80R resistance
without cost or gain on viral fitness in human hosts. Importantly,
the D480G mutation arose from the selection pressure of 80R that
coincides with the change from D480 in S proteins of 2002/03
viruses (SZ3/Tor2) to G480 in 2003/04 viruses (PC04/GD03)
(Table 2).
Selection for BnAbs by de novo human non-immune scFv
library panning against variant S proteins
Having obtained evidence of naturally occurring human and
animal 80R-like nAbs and of a dominant 80R neutralization
escape pathway that appeared to occur during natural SARS/
SARS-like CoV infection, we sought to isolate new BnAbs with
pan-activity against 2002/03 and 2003/04 strains as well as 80R
escape variants and to identify structural features that were unique
and/or common for their broad activity. Signature amino acid
differences in S protein at positions 472 and 480 between 2002/03
and 2003/04 strains provided a finite way to interrogate the
breadth of nAb binding and neutralization activity (Table 2).
Identification of nAb 11A. GD03-RBD was initially used as
bait to isolate cross-strain nAbs that could recognize promiscuous
amino acids at positions 472 and 480. Five unique antibodies
(11A, 10C, 15D, 23E, 28G) were identified by panning against
GD03-RBD-C9 with two non-immune human Ab phage display
libraries and neutralizing activity was tested against pseudotyped
viruses. One of them 11A was found to be a potent nAb against
GD03 but not against Tor2 (Fig. 2A). Kinetic analysis of 11A IgG
binding to GD03-RBD demonstrated high affinity interaction
(KD=2.260.7 nM) (Fig. 2B). 11A also potently inhibited GD03-
RBD’s binding to ACE2 expressing 293T cells (Fig. 2C). Epitope
mapping showed that two amino acids in the GD03-RBD region
(472P and 480G) were critically important for 11A’s binding.
Single amino acid changes at either position resulted in complete
loss of 11A binding (Fig. 2D). Other amino acid changes at
positions of V404A, Y442F, K465A, T468A and S487A did not
affect 11A binding (data not shown). On the basis of this result, all
of the 2004 civet viruses (PC04) should also be recognized and
neutralized by 11A since PC04 has same 472P and 480G as GD03
(Table 2). In contrast to 11A, 80R was only affected by changes at
position 480 but not 472 [23]. As shown in Fig. 2E, 472 is located
on a ridge formed by an extended loop that is reinforced by the
Cys
467-Cys
474 disulfide bond [26]. This suggests that 11A
recognizes a slightly different neutralizing epitope since the 80R
CDR residues do not make contact with this segment of RBD
[24].
Identification of an anti-D480A Ab, 256. In a parallel effort
D480A- or D480G-Tor2 RBD coated on immmunotubes and
conjugated to magnetic beads were used as panning targets
together with a third non-immune scFv library to isolate the
desired BnAbs. Only panning against D480A-magnetic beads
resulted in D480A-RBD specific ELISA positive clones and only
one clone, scFv 256 bound to cell-surface expressed D480A full-
length S protein and showed neutralization activity against D480A
S pseudotyped viruses (data not shown). 256-scFv was converted to
Table 1. Amino acid sequences in spike protein of 80R
neutralization escape mutants.
Amino acid position
82 228 292 421 480
Wild type (Urbani) P I S L D (gat)
80R escape mutants Iso1-100 P I G L G (ggt)
Iso1-101 P I S L A (gct)
Iso1-102 S T S F A (gct)
Iso1-103 P I S L A (gct)
doi:10.1371/journal.ppat.1000197.t001
Table 2. Amino acid differences in the RBD of spikes.
Representative
strain name
GenBank
Accession No. Amino acid position
344 360 472 479 480 487
2002/2003 human outbreak Tor2 AY274119 K F L N D T
2002/2003 Civet SZ3 AY304486 R S L K D S
2003/2004 human outbreak GD03 AY525636 R S P N G S
2003/2004 Civet PC04 AY613951 R S P R G S
doi:10.1371/journal.ppat.1000197.t002
methods were used for the following panels B and D. B, Neutralization assay of Tor2 and GD03 pseudotyped viruses with six civet serum samples
collected from animal market in Guangzhou in Jan. 2004. Similarly as Fig. 1A, ‘‘*’’ indicates the data points for a SARS-CoV negative civet cat serum
sample. C, Neutralization assay of Tor2 and GD03 pseudotyped viruses with four serum samples from 2003/04 outbreak. The samples labeled in the
graph as patient 1–4 that were the same patients described before [5]. D. Ten serum samples from civet cat farmers collected in June 2003in
Guangdong Province were analyzed against Tor2 and GD03 pseudotyped viruses. E, Tor2 -RBD binding activity of 2002/03, 2003/04 outbreak, and
Civet cat farmers’ serum samples were analyzed by ELISA. These serum samples were the same as those used in Panel A, C, and D, respectively.
Dilution of serum was 1:180. The data was presented the same way as panel A and unpaired Student t-test was used for statistical analysis. The
average and standard deviation (SD) of background binding of two SARS-CoV negative human serum samples (Ctrl.HS) were also shown. F, A
comparison of the competition ability of different serum samples for 80R’s binding to Tor2-RBD were evaluated by ELISA. Dilution for all samples was
1:20. The non-specific competition for 80R’s binding to Tor-RBD by two Ctrl. HS or one control civet cat serum (Ctrl.CS) was also shown. Serum
samples were corresponding to those used in panel A, B, C or D. The data presentation and statistic analysis were done the same way as panel E.
doi:10.1371/journal.ppat.1000197.g001
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Tor2-, GD03-, D480A-, and D480G-pseudotyped viruses. As
shown in Fig. 3A, 256-IgG1 neutralized D480A and D480G
(D480A.D480G) but with ,80% activity at the highest Ab
concentration tested (50 mg/mL). It also inhibited Tor2 viral entry
but was much less potent than 80R and only marginally
neutralized GD03. Furthermore, 256-IgG1 showed even lower
neutralization titer in a micro-neutralization assay (Table 3) using
Figure 2. Neutralization of pseudotyped viral infection by anti-GD03 Abs and epitope mapping of GD03 nAb 11A. A, Five anti-GD03
Abs isolated by phage Ab library screening against purified GD03-RBD were analyzed for neutralizing activity using GD03 (Left panel) or Tor2 (Right
panel) spike pseudoyped viruses. B, Kinetic characterization of GD03-RBD binding to 11A-IgG1. Abs were captured on a CM4 chip via immobilized
anti-human IgG1 on the chip. GD03-RBD at various concentrations (2 folds serial dilutions, highest concentration was indicated) was injected over the
chip surface. Binding kinetics was evaluated using a 1:1 interaction model. In each panel, the binding response curves (red lines) are overlaid with the
fit of the interaction model (black lines). All ka, kd, KD value showed in the table represent the means and standard errors of three experiments. C,
Competition of 11A for the binding of GD03-RBD-C9 to 293T-ACE2 cells. GD03-RBD-C9 or control-RBD-C9 (Filled purple) used for staining is at 20 ug/
mL and the Abs (256 or 80R negative control) were used at 50 ug/mL to compete for the binding of GD03-RBD to 293T-ACE2 cells. D, Epitope
mapping of 11A. Purified proteins of a set of GD03-RBD or Tor2-RBD mutants were coated to ELISA plates at indicated concentrations. 2 mg/ml of
11A-IgG1 followed by HRP-anti-human IgG1 were used to detect the binding of 11A with different mutants. E, Interface of structure of the Tor2- RBD/
80R complex
21. S1-RBD is in yellow. CDR loops (H1-H3 and L1-L3) of 80R, amino acids of 80R-CDRL1 and L2 (162–164 and 182) as well as 472L and
480D of S1-RBD are colored as shown.
doi:10.1371/journal.ppat.1000197.g002
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may be explained, at least in part, by the conformational
differences between the recombinant S protein and the S on the
pseudotype or natural virus. Interestingly, kinetic studies showed
that 256-IgG1 had high binding affinity with all three RBDs:
Tor2-, GD03- and D480A-RBD (Fig. 3B). While this discrepancy
between high binding affinity of Ab 256 and weak pseudo/micro
neutralization activity could also be due to conformation
difference of S, alternatively it could be based on 256’s
mechanism of neutralization which is not by direct competition
of S binding to ACE2. As shown in Fig. 3C, Ab 256 does not
compete with Tor2-RBD for cell-surface ACE2 receptor binding
(left panel), but dramatically augmented GD03-RBD’s binding
with ACE2 (right panel). As expected the 256 epitope is also
distinct from 80R and 11A, neither 80R nor 11A competed with
256 for Tor2- (Fig. 3D, left) or GD03-RBD binding (Fig. 3-D,
right) in a competition ELISA assay. Thus, BnAbs against 80R
escape mutant D480A/G as well as 2002/03 and 2003/04 strains
were not isolated through numerous de novo variant S protein
pannings using non-immune Ab-phage libraries.
A structure-based approach to broadening 80R’s
neutralization spectrum through light chain shuffling
and focused mutagenesis
Structural data guided a different approach to engineer 80R to
have more broadly neutralizing activity against D480A/G and
2003/04 outbreak strains. The co-crystal structure of the Tor2-
RBD in complex with 80R shows that D480 lies at the center of
RBD-80R interface. In addition, all of the D480 contacting
residues are located in the Vk light chain. In particular in 80R
CDRL1, D480 makes an intermolecular salt bridge to R162 that is
flanked by two neutral residues: V161 and S163, and an H-bond
to N164 [24]. Other contacting residues are D182 in CDRL2 and
R223 in CDRL3. Notably, amino acids 162–164 form part of a
WRCY ‘‘hot spot’’ motif for AID-mediated somatic hypermuta-
tion (SHM) [27,28] and R162 and N164 are mutated from
germline serine (Fig. 4). This suggested firstly that natural
mutations within this hot spot would likely exist in our circa 10
8
member non-immune Vkappa (Vk) repertoire and secondly, that
focused mutagenesis on this ‘‘hot spot’’ would also provide an
experimental system to test whether mutations within this region
would broaden binding and neutralization activity. Accordingly
two directed approaches, Vk light chain shuffling (cs) and CDRL1
(amino acids 161–164) focused mutagenesis (fm) were simulta-
neously utilized to identify natural or directed variation in critical
Vk contact amino acids, respectively.
Both 80R-Vk-cs and two 80R-fm phage display libraries were
constructed and selected against different RBDs (Table 4). Only
clones that bound to four variant S protein RBDs (Tor2, Tor2-
D480A/G, GD03) were further characterized. Five unique Abs
were identified in the 80R-Vk-cs studies following panning
against D480A-RBD. Remarkably, a common feature of 5
unique Abs recovered is the amino acid changes in CDRL1
region from position aa161–164 that are important contact
residues for D480 in RBD. One consensus change in all cs
mutants is S163N at position 163 (Fig. 4). These 5 Abs
maintained germline D182 in CDRL1 of IGKV3-NL5*01 and
germline R223 in CDRL3 of IGKJ1*01, respectively. These
results provide further evidence for the critical importance of
these CDRL1 contact residues in spike protein binding
specificity. In addition, the finding that these Abs also selectively
used VLs originating from the same rearranged IGKV3-NL5*01
germline gene as the parental Ab 80R (Fig. 4) suggests that this
type of VL structure may provide a critical ‘‘pattern recognition’’
motif for this epitope which is necessary to create the functional
binding site of 80R and its derivatives.
The 80R-fm libraries were panned against three RBD targets,
D480A, D480G and GD03 and five clones that were positive by
ELISA for all four targets (including Tor2) were chosen for further
characterization. The amino acid sequences in CDRL1 (161–164)
of these 5 clones were shown in Fig. 5A. Four of these fm Abs were
identified from D480A and GD03 and one (fm39) from D480G
and GD03 panning. Consistent with the results from the 80R-Vk-
cs studies, four of these fm Abs had the SRN change at position
163 and all five maintained the 164N mutation found in parental
80R. Thus, this ‘‘hot spot’’ is indeed of central importance in
controlling the breadth of binding activity.
Next, eight scFvs were converted to human IgG1 mAbs and
tested for neutralization of pseudotyped viruses. As shown in
Fig. 5A and B, among the three cs-Abs and five fm-Abs, RRN
change at position 162 was associated with increased potency of
cs5 and cs84 whereas RRE charge reversal at 162 was found with
the most potent fm-Abs: fm6 and fm39. Other Abs, cs25, fm4, fm5
and fm12 showed less broad or weak neutralization activity. Thus,
Table 3. Microneutralization (MNt) assay.
Abs* MNt titers** Virus
80R 2560 Wild type SARS-CoV (Urbani)
11A ,20
256 20
80R ,20 80R escape mutant Iso1-100 (D480G)
11A ,20
256 40
80R ,20 80R escape mutant Iso1-103(D480A)
11A ,20
256 40
*Whole IgG1 was used for all antibodies in this assay.
**Reciprocals of the highest dilutions of Abs that showed less than 50%
cytopathic effects in 2 of the 3 wells tested.
doi:10.1371/journal.ppat.1000197.t003
Figure 3. Characterization of Ab 256. A, Neutralization of pseudoviral infection by 256-IgG1. An anti-CXCR4 Ab 33-IgG1[42] was used as a
negative control, 80R and 11A were used as positive control for Tor2- and GD03-viruses, respectively. B, Kinetic characterization of the binding of
spike RBDs to 256-IgG1. Binding kinetics was evaluated similarly as described in Fig. 2. B. C, Competition of 256 for the binding of Tor2- or GD03-RBD-
C9 to 293T-ACE2 cells. Left, competition for the binding of Tor2-RBD-Ig to 293T-ACE2 cells. 0.5 ug/mL of Tor2-RBD-Ig or control-Ig (Filled purple) used
for the staining of 293T-ACE2 cells and the scFvs (control or 256) were used at 5 ug/mL to compete for the binding. Right, competition for the
binding of GD03-RBD to 293T-ACE2 cells. The assay was the same as Fig. 2C except 256 was used here. D, Ab 256 Competition ELISA Assay. A fixed
amount of 256 scFv expressing phages (256-phages) were mixed with various scFv-Fc antibody or full-length IgG1s at indicated antibody
concentration, and the mixtures were then added to Tor2-RBD (left) or GD03-RBD (right) coated ELISA plate. The competition of 256-IgG1s for the
binding of 256-phages to RBDs were determined by measuring the remaining binding of 256-phages using HRP-anti-M13 antibody. 256-phages
homologous to 256-IgG1 were used as positive controls and both showed competition for 256-phage binding to Tor2-RBD and GD03-RBD, 80R or
11A did not show inhibition of 256-phages binding to either Tor2- or GD03-RBDs.
doi:10.1371/journal.ppat.1000197.g003
NAb-Driven SARS-CoV Evolution and Its Blockade
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with activity against four RBD variants.
Kinetic changes on RBD binding resulting from
broadening 80R’s neutralization activity
Five most potent nAbs above (cs5, cs84, fm5, fm6, fm39) were
evaluated further for their binding kinetics and affinity with
various RBDs. The kinetic data obtained from binding of Tor2- or
GD03-RBD to Ab-captured biosensor surfaces were evaluated
using a 1:1 binding model or a two state conformational change
model (Table 5 and Fig. S1). For cs-Abs, the kinetic data fit 1:1
binding model perfectly. The interactions of Tor2 with 80R or fm-
Abs exhibited a double exponential pattern, which is not due to
the heterogeneity of Tor2 and Abs, therefore the kinetic analyses
of these Abs using two state conformational change model are
presented. This suggests that a conformational change may occur
after the formation of the initial binding complex. For the binding
of GD03 to 11A and all the 80R’s cs/fm mutants, kinetic
parameters were derived from 1:1 binding model. Due to the
poorer response of the D480A to nAbs, kinetics could not be
accurately derived; however, the affinity was determined by steady
state affinity model and the biosensor-grams are presented for
qualitative comparisons (Fig. S1).
Table 5 summarizes the kinetics and affinities derived from
different nAbs and models. Of note, the affinity of the cs5 and cs84
Abs for Tor2-RBD was#one-fold lower than 80R however, both
Figure 4. Sequence alignment of the Vk of five Abs identified from 80R-Vk-cs library and 80R. The best-matched germline Vk and Jk
genes of 80R are showed on top of the alignment. CDR regions are labeled in large boxes, amino acid substitutions from germline are colored in blue.
A dash indicates no amino acid at that position. Amino acids 161–164 in CDRL1 were highlighted in pink. All 5 Abs have one consensus change from
S to N at position 163. WRCY hot spots of AID are colored in green.
doi:10.1371/journal.ppat.1000197.g004
Table 4. 80R-cs and 80R-fm libraries and their selection results.
Library Library size
Panning antigen
conjugated on beads
Positive clone screening (‘‘+’’/
total clones tested) *
Unique ‘‘+’’ clones for further
characterization
Vk-cs 6.3610
6 D480A-RBD 154/196 cs-5, cs-25, cs-34, cs-84, cs-110
fm 161–163 1.5610
4 D480A-RBD 77/96 fm4,fm5, fm6,fm12
D480G-RBD 48/96 fm39
162–164 3610
4 GD03-RBD 47/96 fm4,fm5, fm6,fm12,fm39
*Two rounds of selection for 80R- Vk-cs library and one round selection for 80R-fm library were performed before ELISA screening for positive clones.
doi:10.1371/journal.ppat.1000197.t004
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also exhibit a similar high affinity as the potent GD03 nAb 11A for
binding to GD03-RBD, and 0.2–1.4 mM affinity for binding to
D480A-RBD to which neither 80R nor 11A can bind. By
comparison, the fm6 and fm39 Abs have circa 10-fold lower
affinity for Tor2-RBD, but they maintain high affinity binding for
GD03 and are the highest affinity D480A binding Abs that were
isolated.
Discussion
Molecular phylogenic analyses have provided evidence that
positive selection pressure was behind the evolution of SARS-CoV
S gene during and between the two 2002/03 and 2003/04
epidemics [8,9]. However, direct evidence that nAb-mediated
immune pressure is one of the main driving forces of virus
evolution, especially in intra-species transmission, is lacking. In this
study we focused on a critical neutralization epitope and
demonstrate that contemporaneous-strain and cross-strain nAb
responses co-exist during natural SARS-CoV infection of civet cats
and humans. In addition, in vitro nAb escape studies have provided
strong support for the existence of a natural nAb driven evolution
pathway. Moreover, structure-based 80R-VL shuffling and
somatic hypermutation ‘‘hot spot’’ targeted mutagenesis were
successful at generating BnAbs with activity against 80R escape
mutants as well as 2002/03 and 2003/04 strains.
NAb responses were measured in convalescent serum from
chronically exposed civet farmers, 2002/03 and 2003/04 SARS
patients and 2003/04 civet cats against prototypic SARS-CoV
strains Tor2 and GD03 that were representative of the two
zoonotic transfers to humans. NAb levels in convalescent serum
from 2002/03 SARS patients were higher against contemporane-
ous viral strain represented by Tor2 than against the 2003/04
GD03 strain. Similarly, 2004 civet cat serum had higher nAb
levels against GD03 strain than against the 2002/03 Tor2 strain.
In addition, a higher percentage of Tor2-RBD directed Abs in
2002/03 patient serum competed for the 80R epitope, as
compared to chronically exposed, asymptomatic 2003 civet
farmers serum which had similar nAb titers to both Tor2 and
GD03 strains (Fig 1D–F). 2002/03 patient’s serum samples also
Figure 5. Broadly neutralizing activity of cs- and fm-Abs. A, sequence comparison of eight Abs identified from 80R-cs or -fm library selection.
*Amino acid sequence in CDRL1 (161–164). ** 80R was identified from Tor2-S1 targeted library selection [17]; five fm-Abs were from both D480A or
D480G and GD03 targeted library selection. B, Neutralization activity of the eight Abs (full-length IgG1) was tested with the same pseudotyped
viruses as used in Fig. 3A at indicated Ab concentration. Cs5, cs84, fm6 and fm39 appeared to be the four BnAbs.
doi:10.1371/journal.ppat.1000197.g005
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serum samples tested (Fig. 1E–F). These results demonstrated that
cross-neutralization activity was present in all serum samples,
suggesting that some neutralizing epitopes are conserved.
Meanwhile, nAb responses elicited during natural infection clearly
have strain-specific components. Indeed, 80R-like 2002/03 viral
strain specific nAbs were found at higher levels in 2002/03 serum
samples than 2003/04 samples from both animals and humans.
NAbs naturally derived from memory B-cells of a 2002/03
SARS patient that could neutralize both Tor2 and GD03 have
been reported [15,20,29,30]. Among the 23 such nAbs represent-
ing six functional groups based on virus strain cross-reactivity, the
five nAbs in group III are most like 80R in their ability to only
neutralize human isolates from the 2002/03 outbreak [30],
although it is unknown if they have the same D480 dependence
as 80R. NAbs similar to 11A were not identified probably because
this donor was not exposed to the GD03 prototypic isolate with
472P/480G amino acids. Of particular interest is group VI that
contained four BnAbs against all human and animal viruses from
both outbreak strains. This study demonstrates that nAbs with
different activities are produced in serum of naturally infected
hosts and suggests that neutralization activity represents the sum of
these polyclonal nAb responses. Importantly, while memory B cells
producing BnAbs (e.g. Group VI) were elicited during natural
SARS-CoV infection, they may contribute to only a small
percentage (,20% - four out of total 23 nAbs) of the circulating
nAbs [30]).
The potential role of human nAbs for protection against SARS-
CoV infection has been established by several groups [15–19,31].
As a consequence of high mutation rate of these RNA viruses, the
activity of nAbs can be dramatically impacted by neutralizing
escape variants of SARS-CoV. In vitro immune pressure with 80R,
readily gave rise to escape variants at only one amino acid position
(D480A or D480G) with the acquisition of an 80R-resistant
phenotype and the mutation is neutral for viral replication or
fitness in permissive cells. Position 480 has not been identified as a
positively selected site for adaptation to or in human hosts
[8,32,33]. However, the D480G mutation coincides with the
change from D480 in S proteins of all 2002/03 viruses (Tor2 and
SZ3) to G480 in all 2003/04 viruses (GD03 and PC04) (Table 2).
NAb pressure by 80R-like Ab or Group III Abs which exists
naturally could give rise to intermediate D480G escape mutants
that may continue to evolve under immune pressure from SZ3/
Tor2-like strains to PC04/GD03-like strains. Indeed, phylogeny
analysis of S genes from 2003 civets (SZ3) and 2004 civets (PC04)
indicates a positive selection during animal-to-animal transmis-
sion. Thus, in civets, 80R or 80R-like nAbs-mediated immune
pressure could be a major driving force for positive selection of
G480 in PC04 during evolution from SZ3 or a common ancestral
strain (s).
Broadening the activity of human nAbs either naturally by B-
cell hypermutation or synthetically through Ab engineering to
include binding to escape mutants and additional viral strains
could be one way to interfere with the viral evolution pathway and
more efficiently control virus infection in humans. As a first step to
isolating BnAbs with activity against 80R escape mutants as well as
2002/03 and 2003/04 strains, three large non-immune Ab-phage
libraries were used to pan against variant RBD proteins. Since the
GD03 shares the same 480G as 80R escape mutant, we
hypothesized that selection with GD03-RBD may generate new
nAbs, not only against GD03 but also 80R’s resistance mutants.
While nAb 11A was identified with high-affinity binding and
potent neutralization to GD03, it did not neutralize other viral
infections including Tor2, it’s D480A/G mutants and SZ3 (data
Table 5. Kinetics of Ab interactions with Tor2-RBD or GD03-RBD and affinity of Abs binding with D480A-RBD.
1:1 binding model AzB /?
ka
kd
AB Two state conformational change model AzB /?
ka1
kd1
AB ðÞ /?
ka2
kd2
AB ðÞ  
Affinity
model
ka (M
21 s
21610
5) kd (s
21610
23) KD (nM)
ka1
(M
21 s
21610
5)
kd1
(s
21610
22)
ka2
(s
21610
23)
kd2
(s
21610
23) KD (nM) KD (mM)
80R/Tor2 9.364.8 5.863.4 7.360.8 0.460.0 3.260.3
fm5/Tor2 4.462.4 3.360.2 6.060.4 0.360.0 4.061.2
cs84/Tor2 1.261.1 5.0+2.8 5.261.7
cs5/Tor2 7.765.7 4.362.0 6.462.1
fm6/Tor2 2.960.3 6.260.0 13.060.0 1.260.0 17.660.0
fm39/Tor2 2.561.5 9.863.4 14.364.1 1.860.0 51.2621.0
11A/GD03 3.661.3 0.760.7 2.260.7
cs5/GD03 4.761.1 1.360.2 2.860.3
cs84/GD03 3.360.4 1.060.0 2.960.4
fm6/GD03 5.860.5 1.760.1 3.060.4
fm39/GD03 7.760.3 2.860.5 3.660.5
fm5/GD03 11.462.0 42.460.1 38.360.6
fm39/D480A 0.260.0
fm6/D480A 0.260.0
cs5/D480A 0.560.1
fm5/D480A 1.160.3
cs84/D480A 1.460.2
The kinetic data were analyzed by using either the 1:1 interaction model or the two state conformational change model. At least duplicate experiments were run for
each binding interactions. The averaged value for each parameter, together with the standard error, is shown.
doi:10.1371/journal.ppat.1000197.t005
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using D480A/G-Tor2-RBD as library selection. Only one Ab 256
that had extraordinary binding affinity for Tor2, D480A and
GD03 but poor neutralization activity, particularly against the
latter strain was isolated. Unlike 80R and 11A, nAb 256 did not
compete for RBDs binding to ACE2. These results demonstrate
that the strategy of de novo selection with non-immune libraries
against different viral spike proteins is neither efficient nor
sufficient in generating BnAbs with the desired extended spectrum
of activity. Whether this limitation of de novo selection for BnAbs
can be overcome by using immune libraries from SARS-CoV
infected patients remains to be determined.
Structural data obtained from Tor2 RBD-80R scFv co-
crystallographic studies provided a different approach to directly
manipulate 80R to broaden its specificity as an alternative to
antigen-driven passive selections. These studies indicated that
only VL makes significant intermolecular contacts with D480.
Notably, critical contact amino acids R162, S163 and N164 of
CDR1 lie within a predicted ‘‘hot spot’’ for AID mediated
SHM. While combinatorial light chain shuffling has been
reported previously to provide diversity and a drift in viral
epitope recognition [34,35], a focus on a single VL CDR ‘‘hot
spot’’ alone as an immune strategy to broaden nAb activity has
not been reported. We therefore explored 80R-Vk chain
shuffling and focused mutagenesis of amino acids 161–164 as
strategies to broaden the fine specificity of 80R and to overcome
the resistance to D480A/G mutations. In both cases, only small
libraries were found to be necessary to isolate novel nAbs with
the desired properties (Table 4). Vk shuffling library selection
resulted in five new Abs against D480A, with three Abs, cs-5, cs-
25 and cs-84 broadly neutralizing all four viral strains.
Remarkably, sequence analysis revealed the common feature
that all Abs had amino acid changes in the CDRL1 region from
position aa161–164, with a consensus change of SRNa t
position 163. Potency of broad neutralization for cs-5 and cs-84
was further enhanced by the positive to neutral RRNc h a n g ea t
aa162. Additionally, the fm-derived phage display libraries that
carried saturated mutations for 80R CDRL1 amino acids 161–
164 resulted in the isolation of five BnAbs with activity against
the four viral strains. Importantly, the consensus S163N change
was again found and parental 80R Y164N mutational change
was maintained. Thus, the specificity of the high affinity and
potent nAb 80R, that was originally targeted to SARS-CoV
Tor2, was successfully broadened to become active against other
viral strains including GD03 and 80R’s escape mutants without
compromising its original potency against Tor2. These studies
suggest that even without having crystal structure information,
selecting a chain (VH or VL) shuffled library against an escape
mutant will likely provide important paratope information on
regions which could account for the escape from parental Ab.
Likewise, SHM hot-spot targeted mutagenesis strategy may be
of similar great value when it is combined with a known
structure.
Finally, the development of a single nAb or nAb combinations
with sufficient breadth of protection against multiple viral strains
including escape mutants and those that may arise by future
zoonotic transfers is of great importance. One strategy, that we
term ‘‘convergent combination immunotherapy’’ (CCI), focuses on
applying intense nAb immune pressure on a single or overlapping
neutralizing epitope such that neutralization escape is prevented or
would occur at a great cost on viral fitness. Structural data on
SARS-CoV evolution provide support for this concept in that
certain mutations in S1 that overlap with the 80R epitope (e.g.
N479K/R, T487S) result in a circa 20-fold loss in binding affinity
for ACE2 [33]. Success at broadening nAb specificity to include a
dominant D480A/G neutralization escape pathway is the first step
in testing this important hypothesis where engineered broad nAbs
such as 80R-fm6 and/or other 80R-cs/fm variants, could be used
either alone or in combination to manipulate virus evolution and
compromise fitness through Ab blockade of escape pathways.
Other approaches like ‘‘divergent combination immunotherapy’’
(DCI), that target two or more non-overlapping neutralizing
epitopes such as on S1 and S2, are not addressed in this work but
represent another important tactic that could be used with the
potent nAbs discovered here. In a similar manner to mAb
therapies, vaccine strategies could be designed to produce BnAbs
that recognize potential escape variants before they naturally
occur. Indeed, inclusion of in vitro derived escape variants that can
promote AID-mediated sequence diversification of germinal
center B-cells is a vaccine strategy worth further investigation [36].
Materials and Methods
Serum samples
Convalescent serum samples from SARS patients during the 1
st
SARS epidemics in 2003 were collected 90–120 days after the
onset of symptoms from Inner Mongolia Autonomous Region,
China. Four serum samples from 2003/04 sporadic cases were
collected 11 days after onset of symptoms. Serum samples from
healthy blood donors were used as negative controls. The
diagnostic criteria for SARS-CoV infection followed the clinical
description of SARS released by WHO. Ten serum samples from
farmers were collected from a Civet cat farm in Zhaoqing,
Guangdong Province in June 2003. Also included in this study
were six civet serum samples collected from Xinyuan animal
market in Guangzhou prior to culling in Jan. 2004, one sample
collected from a SARS-like-CoV negative civet cat was used as a
control [37]. All the serum samples were collected by China CDC
virologists and were verified to be anti-SARS-CoV Ab positive as
detected by enzyme-linked immunoabsorbent assay (ELISA) using
commercially available diagnostic kits. Civet cat samples were
verified positive for SARS-like-CoV by RT-PCR for the N and P
genes. All of the sera were heat-inactivated at 56uC for 30 mins
prior to performing the experiments.
Neutralization assay with S-protein-pseudotyped
lentiviruses
Full-length S gene of SARS-CoV Tor2 or GD03 was generated
de novo by recursive PCR [23,38]. S variants containing D480A or
D480G mutant were generated by site-directed mutagenesis using
S gene of Tor2 as template. Plasmids encoding full-length S
protein of wild type or variant SARS-CoVs were constructed for
making pseudotyped viruses. S-protein-pseudotyped lentiviruses
expressing a luciferase reporter gene were produced as described
previously [23,39]. Briefly, 293T cells were co-transfected with a
plasmid encoding full-length S protein variants, a plasmid
pCMVDR8.2 encoding HIV-1 Gag-Pol, and a plasmid pHIV-
Luc encoding the firefly luciferase reporter gene under control of
the HIV-1 long terminal repeat. Forty-eight hours posttransfec-
tion, viral supernatants were harvested for neutralization assay.
Testing antibodies or sera at different dilutions were incubated
with adequate amount of S-protein-pseudotyped viruses for
30 mins at room temperature (RT). The mixture was then added
to ACE2-expressing 293T cells in 96 well plates. Infection
efficiency was quantified by measuring the luciferase activity in
the target cells with an EG&G Berthold Microplate Luminometer
LB 96V.
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escape variants
80R escape mutants were generated by incubating an equal
volume (0.5 ml) of wild-type SARS-CoV (Urbani strain,
3610
6 pfu/ml) and 1.5 ug/ml of 80R Ab (giving 90% inhibition
of viral infection) for 1 h at 37uC and 5% CO2. The virus-80R
mixture were added into a monolayer of Vero E6 cells in 6-well
plates and incubated with cells for 1 h at 37uC and 5% CO2, then
the virus was removed and the cells were washed twice with
DMEM medium. Finally, cells were overlaid with 2.5 ml of
5%FBS/DMEM culture medium containing the above concen-
tration of 80R and 1% agarose, incubated for 3 days. 1 ml of 3%
neutral red were added to each well, and left the plates overnight
in 37uC/CO2 incubator. The next day, isolated escape virus
plaques were picked and transferred into medium, freeze-thawed 3
times. The plaque-picked virus was propagated in Vero E6 cells in
the presence of 80R for three passages until a cytopathic effect
(CPE) was evident. The passaged viruses were then incubated with
80R in the plaque assay to confirm an 80R resistance phenotype
and to generate the plaque-purified (subcloned) mutant viruses.
The subclones of the escape virus mutant were then propagated,
aliquoted and stored at 270uC. To identify possible mutations in
the SARS-CoV spike protein of each of the escape viruses, viral
RNA of each of the escape viruses and wild-type SARS-CoV virus
was isolated and converted into cDNA by standard RT-PCR. The
PCR products were cloned by TOPO-cloning vector (Invitrogen),
and 5 clones of each PCR product were analyzed for nucleotide
sequences of the SARS-CoV spike.
Expression and purification of RBD of SARS-CoV variants
and mutants
Plasmids encoding the RBD (residues 318–510) fused C-
terminally with C9 tag were transfected into 293T for expression.
All the mutants of RBD were constructed by site-directed
mutagenesis. D480A- or D480G-RBD was made using Tor2-
RBD as template. Anti-C9 Ab 1D4 (National Cell Culture Center)
was conjugated with protein A Sepharose and used for affinity
purification of RBD-C9.
Construction of 80R-Vk-cs and 80R-fm library
VH (Variable region of heavy chain) gene of 80R was cloned as
a NcoI/BspEI fragment into the vector pFarber-Vk-rep which
contains a repertoire of 1.2610
8 non-immune Vk genes derived
from 57 healthy donors. Ligated DNA was transformed into
eclectroporation-competent E. Coli. TG1 cells following manufac-
ture’s instructions (Stratagene, La Jolla, CA). Three transforma-
tions were performed to generate the 80R-VL-cs-library. For 80R-
fm-library, 80R scFv containing pFarber phagemid was used as
DNA template. Targeting residues were mutated to all 20 amino
acids by using degenerated oligonucleotides contains random
NNK codon (N=A+T+G+C and K=G+T) and QuikChange
method (Stratagene). The NNK codon encodes all 20 amino acids
and UAG stop codon, which can be suppressed in SupE E.Coli
bacterial strains. Mutated pFarber-80R-scFv DNA was electropo-
rated into TG1 cells to generate 80R-fm-library. Phage antibodies
from each libraries were produced as described [40] and used for
panning (selection).
Selection of phage library and screening of S1-RBD-
specific phage antibodies
Three human non-immune scFv libraries were used in this
study. Two of them (a total of 2.7610
10 members) were
constructed from peripheral blood B-cells of 57 un-immunized
donors in our lab (Mehta I/II libraries), and the third one
(2.3610
10) was constructed from 47 healthy donors at Fox Chase
Cancer Center. 80R-Vk-cs library and fm-libraries were described
as above. 5610
11 pfu of phage-scFvs prepared from each library
[40] were used for selection of scFvs against different RBD targets
separately. Purified RBDs were either coated in maxisorp
immunotubes (Nunc, Naperville, IL) or conjugated to magnetic
beads (Dynabeads M-270 Epoxy, Dynal Inc.) following manufac-
turer’s instructions. Immunotube-bound or beads-coupled proteins
were incubated with phage-scFvs from different libraries. Non-
specifically absorbed phages were removed by intensive washings
with PBST (PBS containing 0.05% Tween 20). Specific bound
phages were eluted with 100 mM triethylamine, neutralized by
1 M Tris pH 7.4, infected into TG1 e.coli., amplified and used for
further selections as described previously [40]. Randomly picked
single phage-scFv clones were screened for specific binding to
different RBD targets by ELISA after two rounds of panning.
Clones that bound to targets with A450.1.0 were selected for
further sequence analysis. VH and VL chain of these clones were
sequenced and their corresponding amino acid sequences were
aligned to identify unique clones.
Production of phage-scFvs and whole human IgG1s
Phage-scFvs for individual clones were produced for neutrali-
zation assay using the same method as making phage library [40].
Phage particles were concentrated 25 times (2–6610
13) by using
PEG/NaCl precipitation. Whole human IgG1s were produced as
described previously [17]. In brief, the VH and VL gene fragments
of the selected scFvs were separately sub-cloned into human IgG1
kappa light chain or lambda light chain expression vector TCAE5
or TCAE6 [41]. Human IgG1s were expressed in 293F cells
(Invitrogen) or 293T by transient transfection and purified by
protein A sepharose affinity chromatography.
ELISA and competition ELISA
96-well Maxisorp immunoplates were coated with 0.2 mg
antigen per well or control proteins. Testing human sera, Abs or
phage-Abs in PBS containing 2% nonfat milk were then added.
For competition ELISA, competitive sera or Abs were pre-mixed
with testing Abs for 30 mins at RT and then added. Specific
bound Abs or phage-Abs were detected by adding HRP-
conjugated anti-human IgG or HRP-labeled anti-M13, respec-
tively. TMB substrate for HRP was then added, the reaction was
stopped 5 mins later, and absorbance at 450 nm was measured.
Surface Plasmon Resonance (SPR) analysis
Binding of mAbs to various RBDs were anaylyzed on a Biacore
T100 (Biacore) at 25uC. Anti-human IgG Fc antibody (Biacore)
was covalently coated to CM4 sensor chip by amine-coupling
using the coupling kit (Biacore). Abs were captured onto anti-
human IgG Fc surfaces at the flow rate of 10 ml/min in HBS
buffer (Biacore). RBDs were injected over each flow cell at the flow
rate of 30 ml /min in HBS buffer at concentrations ranging from
0.15 to 100 nM for interactions of Abs with Tor2-RBD or GD03-
RBD, and 15.6 to 2000 nM for the interaction of Abs with
D480A-RBD, respectively. A buffer injection served as a negative
control. Upon completion of each association and dissociation
cycle, surfaces were regenerated with 3 M MgCl2 solution. The
association rates (ka), dissociation rate constants (kd), and affinity
constants (KD) were calculated using Biacore T100 evaluation
software. The goodness of each fit was based on the agreement
between experimental data and the calculated fits, where the Chi
2
values were below 1.0. Surface densities of Abs were optimized to
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means and standard errors of at least two experiments.
Statistics
One-way ANOVA for correlated samples was used to measure
differences between different types of serum samples in neutral-
izing pseudo viral infection. Unpaired Student t-test was used for
statistic analysis of differences between serum samples in binding
to Tor2-RBD and competition ability of 80R’s binding to Tor2-
RBD.
Supporting Information
Figure S1 Biosensorgrams of binding analysis of nAbs with spike
RBDs.
Found at: doi:10.1371/journal.ppat.1000197.s001 (0.61 MB
DOC)
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